Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 3, 1997, Pages 287-291

  Tabone, Marco ^a   Secreto, Paola ^a   Marini, Carla ^a   Bonardi, Renato ^b   Boero, Marco ^c   Taraglio, Stefano ^a   Ercole, Elena ^a   Bruno, Francesca Sallio ^a   Pera, Angelo ^a  

^a MAURIZIANO HOSPITAL   (Italy)

^b Ospedale Martini Nuovo   (Italy)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

Anti HCV IgM; Chronic active hepatitis; Interferon therapy

Indexed keywords

DNA; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; DNA DETERMINATION; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; FERRITIN BLOOD LEVEL; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA; VIRUS REPLICATION;

EID: 0030941715     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199703000-00013     Document Type: Article

References (29)

1. Tiné F, Magrin S, Craxí A, et al.: Interferon for chronic non-A, non-B hepatitis: a meta analysis of randomized clinical trials. J Hepatol 1991, 13:192-199.
2. Causse X, Godinot H, Chevallier M, et al.: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991, 101:497-502.
3. Weiland O, Schvarcz R, Wejstal R, et al.: Therapy of chronic post-transfusion non-A, non- B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990, 11(suppl. 1):S57-S62.
4. Battezzati PM, Podda M, Bruno S, et al.: Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis: preliminary report of a long term trial. Ital J Gastroenterol 1992, 24:481-484.
5. Olynk JK, Reddy KR, Di Bisceglie AM, et al.: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995, 108:1104-1109.
6. Hino K, Sainokami S, Shimoda K, et al.: Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994, 42:299-305.
7. Hagiwara H, Hayashi N, Mita E, et al.: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993, 104:877-883.
8. Lau JY, Davis CL, Kniffen J, et al.: Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 1993, 341:1501-1504.
9. Tsubota A, Chayama K, Ikeda K, et al.: Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection. Hepatology 1994, 19:1088-1094.
10. Martinot-Peignoux M, Marcellin P, Pouleau M, et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995, 22:1050-1056.
11. Brunetto MR, Oliveri F, Rocca C, et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen. Hepatology 1989, 10:198-202.
12. Smith HM, Lau JYN, Daniels HM, et al.: Significance of IgM anti-HBc in chronic hepatitis B virus infection. J Med Virol 1992, 36:16-20.
13. Farci P, Gerin JL, Aragona M, et al.: Diagnostic and prognostic significance of the IgM antibody to hepatitis delta virus. JAMA 1986, 255:1443-1446.
14. Pawlotsky JM, Remire J, Darthuy F, et al.: Is the detection of anti-hepatitis C virus core IgM influenced by the presence of serum rheumatoid factor? J Med Virol 1995, 45:68-70.
15. Pawlotsky JM, Ben Yahia M, André C, et al.: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994, 19:841-848.
16. Tassopoulos NC, Hatzakis AE, Papatheodoridis GV, et al.: Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. J Hepatol 1994, 20:305-311.
17. Negro F, Abate ML, Mondardini A, et al.: The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon. J Viral Hepat 1995, 2:171-174.
18. Pawlotsky JM, Darthuy F, Remiré J, et al.: Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C. J Med Virol 1995, 47:285-291.
19. Yuki N, Hayashi N, Kazuyoshi O, et al.: The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 1995, 22:402-406.
20. Martinelli ALC, Brown D, Braun HB, et al.: Quantitative assessment of hepatitis C virus RNA and IgM antibodies to hepatitis C core in chronic hepatitis C. J Hepatol 1996, 24:21-26.
21. Picciotto A, Icardi GC, Bardellini E, et al.: Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon. Eur J Gastroenterol Hepatol 1995, 7:623-625.
22. Quiroga JA, van Binsbergen J, Wang CY, et al.: Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity and liver disease outcome. Hepatology 1995, 22:1635-1640.
23. Tabone M, Galatola G, Secreto P, et al.: Serum levels of anti-hepatitis C virus IgM core antibodies may predict the response to interferon-alfa therapy in chronic hepatitis C. J Viral Hepat 1994, 1:155-157.
24. Stuyver L, Rossau R, Wyseur A, et al.: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993, 74:1093-1102.
25. Ishak K, Baptista A, Bianchi L, et al.: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
26. Hoofnagle JK, Mullen KD, Jones DB, et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986, 315:1575-1578.
27. Chemello L, Bonetti P, Cavalletto L, et al.: Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995, 22:700-706.
28. Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three alfa 2b interferon regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995, 332:1457-1462.
29. Chen M, Sonnerborg A, Sallberg M: Levels of hepatitis C virus RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein. J Clin Microbiol 1995, 33:778-780.